ChartRow logo
XERS
$11.13+1.64%
as of close, Oct 20, 2026
☾ AH $11.13 +1.64%
PeersMRNALLYMDTUNHJNJTMO
Share this page

Xeris Biopharma Holdings Inc. trailing returns

How Xeris Biopharma Holdings Inc. (XERS) has performed over the last day, week, month and year, over 5 years, and since inception, through October 20, 2026 — price return and dividends side by side, with the worst drop inside each window.

Trailing returns by period#

To 2026-10-20. Price return + dividends = total return. Per year (CAGR) for windows of a year or more, with the cumulative total return beneath. Worst drop: the deepest fall in the price from a high inside the window, and when it bottomed.

PeriodPriceDivsTotalWorst drop
1 day+1.6%+0.0%+1.6%—
5 days+9.1%+0.0%+9.1%-4.2%Oct 14
1 month+35.7%+0.0%+35.7%-9.0%Oct 2
YTD+41.8%+0.0%+41.8%-34.9%Mar 24
1 year+19.2%+0.0%+19.2%-46.6%Mar 2026
5 years+41.0%+0.0%+41.0%+456.5%-64.8%Jan 2023
Since inception (2018)-6.9%+0.0%-6.9%-45.0%-96.2%Jan 2023

Growth of XERS#

Actual level with dividends reinvested (solid); dashed lines are each window's constant-rate path from start to today.

  • 5 years+41.0%/year · +456.5%

Methodology#

Trailing returns measure from the closest close about N years before the latest close (2026-10-20). Cumulative return is the total change over the window; annualized return is the compound annual growth rate (CAGR), shown for windows of a year or more. Price return is the change in XERS's closing price; total return reinvests dividends (from its split- and dividend-adjusted closes); the dividends column is the difference between the two. The worst drop is the largest fall in the closing price from a high to a later low inside the window, the way a drawdown is usually quoted. See the year-by-year returns for the calendar breakdown. Past performance does not predict future returns; not investment advice.

FAQ#

What is Xeris Biopharma Holdings Inc.'s return since inception?
Since 2018, Xeris Biopharma Holdings Inc. (XERS) has compounded at about -6.9% a year — -45.0% in total.

More on Xeris Biopharma Holdings Inc.